Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Competition Fails To Rein In Cancer Drug Prices

Executive Summary

A new analysis published in the public policy journal Health Affairs turns the attention of high drug prices, which lately has focused on hepatitis C medicines or companies like Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals Inc., back on oncology therapies – pointing out that competition in that space has done little to bring down the costs of those medications.


Related Content

Regrets For Valeant's Ackman, Pearson; Big Pay For Papa
Beware The 'Pitchforks,' Pharma
It Was Shkreli's Show, But Pharma Was On Trial
Senators Fear Viral Spread Of Gilead Pricing Strategy
ASCO 2014: High cancer costs: Not 'victimless' for anyone


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts